Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Ionis Pharmaceuticals Inc
IONS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$42.93
-0.98
-2.23%
Ult. Agg.: Oct 23, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Ionis Pharmaceuticals Financials
Ionis Pharmaceuticals (IONS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks
Alnylam cut its 2026 sales outlook despite a Q2 earnings beat as slower ATTR-CM market growth weighed on expectations and investors reacted.
Vandana Singh
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio
Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.
Vandana Singh
PRO
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est
Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $895.148 million estimate.
Benzinga Newsdesk
PRO
Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate
Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.07) by 60.75 percent. This is a 149.41 percent decrease over earnings of $0.85 per
Benzinga Newsdesk
PRO
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $893.928M Est
Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $893.928 million estimate.
Benzinga Newsdesk
Stock Market Today: S&P 500, Nasdaq 100, Dow Jones Futures Rise as US-Iran Exchange Strikes—Levi Strauss, AZZ, Ionis Pharma In Focus (UPDATED)
U.S. stock futures advanced on Thursday, as the Dow Jones, Nasdaq 100, and S&P 500 indices rose, following Wednesday's mixed close.
Rishabh Mishra
